Jayashree Kalpathy-Cramer
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 38 | 2025 | 295 | 5.650 |
Why?
| | Retinopathy of Prematurity | 34 | 2024 | 156 | 5.620 |
Why?
| | Image Processing, Computer-Assisted | 22 | 2025 | 748 | 3.220 |
Why?
| | Glioblastoma | 15 | 2024 | 341 | 3.110 |
Why?
| | Brain Neoplasms | 23 | 2024 | 1267 | 3.100 |
Why?
| | Algorithms | 38 | 2024 | 1740 | 2.450 |
Why?
| | Diagnostic Imaging | 19 | 2024 | 320 | 2.230 |
Why?
| | Machine Learning | 21 | 2024 | 517 | 2.170 |
Why?
| | Radiology | 10 | 2024 | 164 | 1.950 |
Why?
| | Natural Language Processing | 7 | 2023 | 95 | 1.890 |
Why?
| | Magnetic Resonance Imaging | 41 | 2024 | 3637 | 1.870 |
Why?
| | Information Storage and Retrieval | 8 | 2015 | 119 | 1.720 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2025 | 282 | 1.660 |
Why?
| | Neuroimaging | 7 | 2022 | 263 | 1.550 |
Why?
| | Glioma | 8 | 2022 | 407 | 1.430 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 5 | 2016 | 138 | 1.290 |
Why?
| | Image Interpretation, Computer-Assisted | 13 | 2025 | 272 | 1.210 |
Why?
| | Software | 10 | 2024 | 668 | 1.080 |
Why?
| | Papillomavirus Infections | 5 | 2025 | 377 | 1.070 |
Why?
| | Optic Disk | 2 | 2025 | 52 | 0.980 |
Why?
| | Humans | 158 | 2025 | 138651 | 0.950 |
Why?
| | Glaucoma | 2 | 2025 | 241 | 0.900 |
Why?
| | Tomography, X-Ray Computed | 15 | 2023 | 2698 | 0.890 |
Why?
| | Severity of Illness Index | 9 | 2024 | 2851 | 0.880 |
Why?
| | ROC Curve | 15 | 2024 | 562 | 0.870 |
Why?
| | Telemedicine | 7 | 2023 | 873 | 0.860 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 234 | 0.860 |
Why?
| | Reproducibility of Results | 28 | 2025 | 3307 | 0.830 |
Why?
| | Radiology Information Systems | 4 | 2022 | 29 | 0.790 |
Why?
| | Solitary Pulmonary Nodule | 3 | 2021 | 21 | 0.790 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2212 | 0.790 |
Why?
| | Privacy | 1 | 2023 | 42 | 0.780 |
Why?
| | Ophthalmology | 5 | 2023 | 104 | 0.780 |
Why?
| | Retina | 6 | 2023 | 305 | 0.780 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2018 | 50 | 0.760 |
Why?
| | Infant, Newborn | 34 | 2024 | 6144 | 0.730 |
Why?
| | Radiologists | 4 | 2024 | 49 | 0.720 |
Why?
| | Ophthalmoscopy | 8 | 2024 | 38 | 0.710 |
Why?
| | Gestational Age | 17 | 2024 | 916 | 0.670 |
Why?
| | Sensitivity and Specificity | 14 | 2024 | 1941 | 0.660 |
Why?
| | Crowdsourcing | 1 | 2020 | 18 | 0.660 |
Why?
| | Fundus Oculi | 5 | 2025 | 74 | 0.640 |
Why?
| | Retinal Vessels | 6 | 2024 | 72 | 0.630 |
Why?
| | Medicine | 1 | 2021 | 125 | 0.630 |
Why?
| | Breast Density | 3 | 2024 | 7 | 0.610 |
Why?
| | Mammography | 4 | 2024 | 156 | 0.590 |
Why?
| | Stroke | 3 | 2023 | 1136 | 0.580 |
Why?
| | Retinal Vein | 4 | 2021 | 13 | 0.550 |
Why?
| | Retrospective Studies | 26 | 2025 | 15909 | 0.550 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2017 | 58 | 0.540 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 108 | 0.500 |
Why?
| | Lung Neoplasms | 5 | 2021 | 2527 | 0.500 |
Why?
| | Tumor Burden | 4 | 2023 | 309 | 0.490 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 95 | 0.490 |
Why?
| | Databases, Factual | 8 | 2021 | 1415 | 0.470 |
Why?
| | Quinolines | 1 | 2016 | 150 | 0.470 |
Why?
| | Gallbladder Neoplasms | 3 | 2011 | 19 | 0.470 |
Why?
| | Female | 56 | 2025 | 73763 | 0.460 |
Why?
| | Peripheral Arterial Disease | 4 | 2023 | 486 | 0.460 |
Why?
| | Radiography, Thoracic | 5 | 2022 | 172 | 0.460 |
Why?
| | Prostatic Neoplasms | 5 | 2024 | 1044 | 0.450 |
Why?
| | Pattern Recognition, Automated | 5 | 2023 | 74 | 0.450 |
Why?
| | Benchmarking | 6 | 2024 | 187 | 0.450 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2025 | 44 | 0.430 |
Why?
| | Cervix Uteri | 2 | 2025 | 52 | 0.430 |
Why?
| | Delivery of Health Care | 1 | 2021 | 958 | 0.430 |
Why?
| | Early Detection of Cancer | 5 | 2025 | 426 | 0.430 |
Why?
| | Subtraction Technique | 1 | 2014 | 25 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1057 | 0.420 |
Why?
| | Radiation Oncology | 2 | 2014 | 85 | 0.420 |
Why?
| | Photography | 6 | 2021 | 108 | 0.420 |
Why?
| | Retinal Artery | 3 | 2021 | 17 | 0.420 |
Why?
| | Chemoradiotherapy | 6 | 2018 | 230 | 0.420 |
Why?
| | Vocabulary, Controlled | 1 | 2014 | 47 | 0.420 |
Why?
| | White Matter | 3 | 2023 | 144 | 0.410 |
Why?
| | Phantoms, Imaging | 7 | 2023 | 144 | 0.410 |
Why?
| | Multimodal Imaging | 1 | 2014 | 117 | 0.400 |
Why?
| | Male | 51 | 2025 | 68260 | 0.390 |
Why?
| | Datasets as Topic | 5 | 2021 | 125 | 0.380 |
Why?
| | Middle Aged | 31 | 2025 | 33604 | 0.370 |
Why?
| | Survival Analysis | 4 | 2016 | 1309 | 0.370 |
Why?
| | Aged | 29 | 2025 | 24024 | 0.370 |
Why?
| | Cerebral Blood Volume | 3 | 2020 | 5 | 0.360 |
Why?
| | Contrast Media | 9 | 2020 | 463 | 0.350 |
Why?
| | Radiotherapy, Conformal | 1 | 2011 | 73 | 0.350 |
Why?
| | Internet | 2 | 2014 | 669 | 0.350 |
Why?
| | Mass Screening | 4 | 2025 | 1292 | 0.350 |
Why?
| | Clinical Competence | 2 | 2016 | 1149 | 0.350 |
Why?
| | Adrenoleukodystrophy | 2 | 2023 | 9 | 0.340 |
Why?
| | Proportional Hazards Models | 4 | 2011 | 1229 | 0.330 |
Why?
| | Brain | 8 | 2021 | 2792 | 0.330 |
Why?
| | Precision Medicine | 3 | 2024 | 424 | 0.320 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 2 | 2023 | 116 | 0.320 |
Why?
| | Medical Informatics | 4 | 2020 | 101 | 0.310 |
Why?
| | Neoplasms | 7 | 2024 | 2681 | 0.310 |
Why?
| | Head and Neck Neoplasms | 5 | 2020 | 549 | 0.310 |
Why?
| | Database Management Systems | 1 | 2008 | 51 | 0.290 |
Why?
| | User-Computer Interface | 4 | 2015 | 164 | 0.280 |
Why?
| | Endovascular Procedures | 2 | 2023 | 349 | 0.280 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 215 | 0.280 |
Why?
| | Automation | 5 | 2020 | 99 | 0.270 |
Why?
| | Infant, Premature | 9 | 2024 | 578 | 0.270 |
Why?
| | Observer Variation | 4 | 2024 | 350 | 0.270 |
Why?
| | Lung | 6 | 2022 | 4106 | 0.260 |
Why?
| | Prognosis | 9 | 2024 | 3984 | 0.260 |
Why?
| | Adult | 26 | 2025 | 38201 | 0.260 |
Why?
| | Radiography | 5 | 2022 | 841 | 0.240 |
Why?
| | Neonatal Screening | 4 | 2023 | 167 | 0.230 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2018 | 154 | 0.230 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2007 | 230 | 0.230 |
Why?
| | Predictive Value of Tests | 5 | 2025 | 2030 | 0.230 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2152 | 0.230 |
Why?
| | Rectal Neoplasms | 2 | 2021 | 148 | 0.230 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2015 | 54 | 0.230 |
Why?
| | Reference Standards | 7 | 2021 | 184 | 0.220 |
Why?
| | Neoplasm Grading | 3 | 2024 | 305 | 0.210 |
Why?
| | Adenocarcinoma in Situ | 1 | 2023 | 1 | 0.210 |
Why?
| | Forecasting | 3 | 2019 | 382 | 0.210 |
Why?
| | Statistics as Topic | 2 | 2014 | 298 | 0.200 |
Why?
| | Postoperative Care | 2 | 2019 | 274 | 0.200 |
Why?
| | Ranibizumab | 1 | 2023 | 21 | 0.200 |
Why?
| | Imaging, Three-Dimensional | 4 | 2023 | 564 | 0.200 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2016 | 137 | 0.190 |
Why?
| | Macular Degeneration | 1 | 2024 | 166 | 0.190 |
Why?
| | Neovascularization, Pathologic | 3 | 2024 | 296 | 0.190 |
Why?
| | Biomedical Research | 3 | 2024 | 694 | 0.190 |
Why?
| | Diagnosis, Computer-Assisted | 2 | 2021 | 87 | 0.190 |
Why?
| | Long QT Syndrome | 1 | 2023 | 67 | 0.190 |
Why?
| | Oxygen | 2 | 2021 | 977 | 0.190 |
Why?
| | Documentation | 2 | 2015 | 198 | 0.190 |
Why?
| | Computer Communication Networks | 2 | 2020 | 33 | 0.180 |
Why?
| | Quality Assurance, Health Care | 2 | 2014 | 331 | 0.180 |
Why?
| | Rheumatic Diseases | 1 | 2022 | 83 | 0.180 |
Why?
| | Infant | 11 | 2024 | 9574 | 0.180 |
Why?
| | Diverticulitis | 1 | 2021 | 8 | 0.180 |
Why?
| | Patient-Specific Modeling | 2 | 2024 | 42 | 0.180 |
Why?
| | Biomarkers | 4 | 2018 | 4092 | 0.180 |
Why?
| | Cohort Studies | 6 | 2022 | 5697 | 0.170 |
Why?
| | Hospital Units | 1 | 2021 | 32 | 0.170 |
Why?
| | Racism | 1 | 2023 | 137 | 0.170 |
Why?
| | Musculoskeletal System | 1 | 2021 | 49 | 0.170 |
Why?
| | Intestinal Obstruction | 1 | 2021 | 52 | 0.170 |
Why?
| | India | 1 | 2021 | 203 | 0.170 |
Why?
| | Dacarbazine | 3 | 2015 | 98 | 0.170 |
Why?
| | Tibial Meniscus Injuries | 1 | 2021 | 48 | 0.170 |
Why?
| | Perfusion Imaging | 1 | 2020 | 62 | 0.160 |
Why?
| | Microcirculation | 2 | 2017 | 150 | 0.160 |
Why?
| | Biomarkers, Tumor | 3 | 2016 | 1224 | 0.160 |
Why?
| | Radiometry | 1 | 2020 | 50 | 0.160 |
Why?
| | Hyperemia | 1 | 2020 | 49 | 0.160 |
Why?
| | Health Information Exchange | 1 | 2020 | 24 | 0.160 |
Why?
| | Medical Records Systems, Computerized | 2 | 2013 | 95 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2022 | 162 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2015 | 638 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2023 | 343 | 0.160 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2017 | 147 | 0.160 |
Why?
| | Area Under Curve | 4 | 2021 | 319 | 0.160 |
Why?
| | Brain Diseases | 1 | 2021 | 148 | 0.160 |
Why?
| | Lung Injury | 1 | 2022 | 224 | 0.160 |
Why?
| | Medulloblastoma | 1 | 2022 | 202 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 104 | 0.160 |
Why?
| | Low Back Pain | 1 | 2021 | 107 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 549 | 0.150 |
Why?
| | Appendicitis | 1 | 2021 | 139 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2023 | 661 | 0.150 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2018 | 70 | 0.150 |
Why?
| | Aneurysm, Ruptured | 1 | 2019 | 35 | 0.150 |
Why?
| | Capillary Permeability | 1 | 2019 | 147 | 0.150 |
Why?
| | Age Determination by Skeleton | 1 | 2018 | 15 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 801 | 0.150 |
Why?
| | Blood-Brain Barrier | 2 | 2017 | 141 | 0.150 |
Why?
| | Models, Biological | 4 | 2024 | 1806 | 0.150 |
Why?
| | Risk Factors | 8 | 2023 | 10252 | 0.150 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2018 | 27 | 0.150 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 245 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 815 | 0.140 |
Why?
| | Linear Models | 1 | 2021 | 852 | 0.140 |
Why?
| | Intracranial Aneurysm | 1 | 2019 | 98 | 0.140 |
Why?
| | Arteries | 2 | 2019 | 263 | 0.140 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 239 | 0.140 |
Why?
| | Prospective Studies | 7 | 2023 | 7554 | 0.140 |
Why?
| | Medical Record Linkage | 1 | 2018 | 67 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1742 | 0.140 |
Why?
| | Global Health | 1 | 2021 | 383 | 0.140 |
Why?
| | Bayes Theorem | 2 | 2016 | 412 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2023 | 10923 | 0.130 |
Why?
| | Gadolinium | 1 | 2017 | 81 | 0.130 |
Why?
| | Polysaccharides, Bacterial | 1 | 2017 | 69 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1482 | 0.130 |
Why?
| | Preoperative Period | 1 | 2017 | 142 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.130 |
Why?
| | Gray Matter | 1 | 2018 | 81 | 0.130 |
Why?
| | Patient Readmission | 1 | 2022 | 703 | 0.130 |
Why?
| | North America | 3 | 2024 | 304 | 0.130 |
Why?
| | Computer Simulation | 5 | 2024 | 996 | 0.130 |
Why?
| | Chronic Pain | 1 | 2021 | 272 | 0.130 |
Why?
| | Skin Diseases, Genetic | 1 | 2016 | 13 | 0.130 |
Why?
| | Pharyngeal Muscles | 1 | 2016 | 5 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 180 | 0.120 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2016 | 20 | 0.120 |
Why?
| | SEER Program | 3 | 2011 | 220 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 2 | 2016 | 230 | 0.120 |
Why?
| | Risk Assessment | 4 | 2025 | 3433 | 0.120 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2020 | 48 | 0.120 |
Why?
| | Blood Volume Determination | 1 | 2015 | 5 | 0.120 |
Why?
| | Vascular Malformations | 1 | 2016 | 51 | 0.120 |
Why?
| | Liver Cirrhosis | 1 | 2017 | 278 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 812 | 0.120 |
Why?
| | Positron-Emission Tomography | 4 | 2021 | 304 | 0.110 |
Why?
| | Fibrosis | 1 | 2017 | 539 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 2015 | 85 | 0.110 |
Why?
| | Physical Phenomena | 1 | 2014 | 13 | 0.110 |
Why?
| | Organs at Risk | 1 | 2014 | 35 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2018 | 7677 | 0.110 |
Why?
| | Societies, Medical | 3 | 2024 | 839 | 0.110 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2844 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2016 | 147 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 669 | 0.110 |
Why?
| | Birth Weight | 3 | 2023 | 508 | 0.110 |
Why?
| | Brachial Plexus | 1 | 2014 | 33 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 788 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2011 | 44 | 0.110 |
Why?
| | Deglutition Disorders | 1 | 2016 | 148 | 0.110 |
Why?
| | Joint Instability | 1 | 2016 | 167 | 0.110 |
Why?
| | Mutation | 3 | 2024 | 3987 | 0.100 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 68 | 0.100 |
Why?
| | Arteriovenous Malformations | 1 | 2013 | 29 | 0.100 |
Why?
| | Computer Literacy | 1 | 2013 | 5 | 0.100 |
Why?
| | Bias | 3 | 2024 | 226 | 0.100 |
Why?
| | Health Information Systems | 1 | 2013 | 16 | 0.100 |
Why?
| | Young Adult | 7 | 2018 | 13305 | 0.100 |
Why?
| | Survival Rate | 3 | 2018 | 1935 | 0.090 |
Why?
| | Terminology as Topic | 1 | 2014 | 243 | 0.090 |
Why?
| | Otorhinolaryngologic Neoplasms | 1 | 2011 | 2 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2014 | 980 | 0.090 |
Why?
| | Nomograms | 1 | 2011 | 54 | 0.090 |
Why?
| | Workload | 1 | 2013 | 162 | 0.090 |
Why?
| | Research Design | 2 | 2014 | 1118 | 0.090 |
Why?
| | Child | 8 | 2024 | 21921 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1729 | 0.080 |
Why?
| | Support Vector Machine | 2 | 2021 | 37 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2116 | 0.080 |
Why?
| | Liver | 1 | 2017 | 1805 | 0.080 |
Why?
| | Periodicals as Topic | 1 | 2012 | 212 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2023 | 133 | 0.070 |
Why?
| | Oregon | 1 | 2008 | 73 | 0.070 |
Why?
| | Exercise | 1 | 2020 | 2072 | 0.070 |
Why?
| | United States | 5 | 2024 | 14938 | 0.070 |
Why?
| | Total Quality Management | 1 | 2008 | 61 | 0.070 |
Why?
| | Lower Extremity | 2 | 2023 | 434 | 0.070 |
Why?
| | MEDLINE | 1 | 2008 | 22 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5112 | 0.070 |
Why?
| | Dilatation, Pathologic | 2 | 2018 | 60 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 907 | 0.070 |
Why?
| | Breast | 2 | 2019 | 158 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2015 | 1092 | 0.060 |
Why?
| | Monte Carlo Method | 2 | 2017 | 143 | 0.060 |
Why?
| | Cluster Analysis | 1 | 2007 | 517 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2019 | 273 | 0.060 |
Why?
| | Tanzania | 1 | 2025 | 56 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2025 | 60 | 0.060 |
Why?
| | Proof of Concept Study | 1 | 2024 | 85 | 0.050 |
Why?
| | Critical Illness | 2 | 2021 | 831 | 0.050 |
Why?
| | Netherlands | 1 | 2024 | 87 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 258 | 0.050 |
Why?
| | Kinetics | 2 | 2019 | 1645 | 0.050 |
Why?
| | Physicians | 1 | 2013 | 932 | 0.050 |
Why?
| | Colposcopy | 1 | 2023 | 21 | 0.050 |
Why?
| | Brain Infarction | 1 | 2023 | 23 | 0.050 |
Why?
| | DNA, Viral | 1 | 2025 | 365 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 65 | 0.050 |
Why?
| | Models, Theoretical | 2 | 2021 | 578 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 30 | 0.050 |
Why?
| | DNA Helicases | 1 | 2024 | 138 | 0.050 |
Why?
| | Data Curation | 1 | 2022 | 19 | 0.050 |
Why?
| | Smartphone | 1 | 2023 | 88 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2022 | 75 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5520 | 0.050 |
Why?
| | Quinazolines | 2 | 2013 | 249 | 0.050 |
Why?
| | Logistic Models | 2 | 2021 | 2065 | 0.050 |
Why?
| | Limb Salvage | 1 | 2022 | 65 | 0.050 |
Why?
| | Health Services | 1 | 2022 | 117 | 0.050 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2024 | 190 | 0.050 |
Why?
| | Vagina | 1 | 2024 | 194 | 0.050 |
Why?
| | Utilization Review | 1 | 2021 | 41 | 0.040 |
Why?
| | Edema | 1 | 2022 | 129 | 0.040 |
Why?
| | Receptors, GABA | 1 | 2021 | 14 | 0.040 |
Why?
| | Nepal | 1 | 2021 | 29 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 412 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2023 | 314 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3523 | 0.040 |
Why?
| | Massachusetts | 1 | 2021 | 173 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1034 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 239 | 0.040 |
Why?
| | Seizures | 1 | 2024 | 431 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1842 | 0.040 |
Why?
| | Abdomen | 1 | 2021 | 135 | 0.040 |
Why?
| | Incidence | 2 | 2020 | 2747 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 616 | 0.040 |
Why?
| | Ankle | 1 | 2020 | 60 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 158 | 0.040 |
Why?
| | Models, Statistical | 2 | 2016 | 663 | 0.040 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 29 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2023 | 410 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2749 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2024 | 706 | 0.040 |
Why?
| | Hand Bones | 1 | 2018 | 2 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 141 | 0.040 |
Why?
| | Risk | 1 | 2021 | 893 | 0.040 |
Why?
| | Bevacizumab | 1 | 2019 | 139 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 171 | 0.040 |
Why?
| | Arthroscopy | 1 | 2021 | 237 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 796 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 53 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 279 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 799 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2019 | 124 | 0.040 |
Why?
| | Medical Oncology | 1 | 2021 | 304 | 0.040 |
Why?
| | Hemizygote | 1 | 2017 | 5 | 0.040 |
Why?
| | Carbon Tetrachloride | 1 | 2017 | 13 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 194 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 146 | 0.030 |
Why?
| | Diffusion | 1 | 2017 | 121 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 161 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 375 | 0.030 |
Why?
| | Skull | 1 | 2018 | 150 | 0.030 |
Why?
| | Ecosystem | 1 | 2022 | 573 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 90 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 685 | 0.030 |
Why?
| | Outpatients | 1 | 2021 | 419 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 330 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2016 | 64 | 0.030 |
Why?
| | Information Dissemination | 1 | 2019 | 221 | 0.030 |
Why?
| | Expert Systems | 1 | 2016 | 4 | 0.030 |
Why?
| | Prostate | 1 | 2017 | 173 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 670 | 0.030 |
Why?
| | Palate, Soft | 1 | 2016 | 15 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 746 | 0.030 |
Why?
| | Video Recording | 1 | 2017 | 181 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1697 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 142 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 175 | 0.030 |
Why?
| | Antineoplastic Protocols | 1 | 2015 | 2 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 243 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 85 | 0.030 |
Why?
| | Molecular Imaging | 1 | 2016 | 55 | 0.030 |
Why?
| | Perfusion | 1 | 2016 | 225 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 281 | 0.030 |
Why?
| | Motion | 1 | 2015 | 99 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2017 | 269 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 76 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 704 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1518 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 853 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2014 | 37 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 734 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1656 | 0.030 |
Why?
| | Image Enhancement | 1 | 2015 | 191 | 0.030 |
Why?
| | Carcinoma | 1 | 2016 | 229 | 0.030 |
Why?
| | DNA Modification Methylases | 1 | 2013 | 17 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 28 | 0.030 |
Why?
| | Child, Preschool | 2 | 2018 | 11158 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2015 | 227 | 0.020 |
Why?
| | Argentina | 1 | 2013 | 27 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1641 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 413 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 433 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2013 | 167 | 0.020 |
Why?
| | Adolescent | 3 | 2018 | 21564 | 0.020 |
Why?
| | Life Tables | 1 | 2011 | 19 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 231 | 0.020 |
Why?
| | Hemodynamics | 1 | 2016 | 1093 | 0.020 |
Why?
| | Smoking | 1 | 2019 | 1591 | 0.020 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2011 | 9 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 849 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 320 | 0.020 |
Why?
| | Time Factors | 1 | 2022 | 6851 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6829 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2235 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1047 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 462 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1242 | 0.020 |
Why?
| | Probability | 1 | 2011 | 308 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1068 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2011 | 323 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1765 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5594 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 896 | 0.020 |
Why?
| | PubMed | 1 | 2008 | 11 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 745 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4315 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1372 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1157 | 0.010 |
Why?
| | Internship and Residency | 1 | 2014 | 1187 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3256 | 0.010 |
Why?
| | Mice | 1 | 2017 | 17814 | 0.010 |
Why?
| | Animals | 1 | 2017 | 37217 | 0.010 |
Why?
|
|
Kalpathy-Cramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|